Market Overview

Watson Pharma's Generic Lysteda Receives FDA Approval


Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. – Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda®.  

Watson intends to begin shipping the product immediately.  Lysteda® is indicated for the treatment of cyclic heavy menstrual bleeding.  Ferring B.V. has filed lawsuits against Watson, alleging that Watson's ANDA product infringes U.S. Patent Nos. 7,947,739, 8,022,106, and 8,273,795.  The litigations remain pending.

For the 12 months ending November 30, 2012, Lysteda® had total U.S. sales of approximately $25 million according to IMS Health data. 

Posted-In: News FDA


Related Articles (WPI)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Spectrum Brands Announces Pres of United Pet Group Unit Heil to Retire

ThermoGenesis Announces Sale of Thermoline Product Line to Helmer Scientific